Biology of the papillomavirus E5 oncoprotein family
Biology of the papillomavirus E5 oncoprotein family
批准号:
7386793
负责人:
Richard Schlegel
金额:
$49.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-01-01 至 2011-02-28
关键词:
AlkalinizationAnchorage-Independent GrowthAneuploidyAppendixBindingBiologicalBiological AssayBiologyC-terminalCancer EtiologyCaveolinsCell Differentiation processCellsCervicalCessation of lifeCharacteristicsCollaborationsCommunicationComplexConnexinsContact InhibitionDetergentsDifferentiation and GrowthDisruptionEndosomesEpidermal Growth Factor ReceptorEpidermisEvolutionFamilyFibroblastsGap JunctionsGenesGoalsGrantGrowthGrowth Factor ReceptorsHumanHuman papillomavirus 16In VitroInfectionIntercellular JunctionsIntracellular MembranesKnockout MiceKnowledgeLaboratoriesLinkMaintenanceMalignant NeoplasmsMalignant neoplasm of cervix uteriMeasuresMediatingMembraneMembrane LipidsMembrane MicrodomainsModelingMolecular TargetMonitorMusNeoplasmsNumbersOncogene ProteinsOncogenesOncogenic VirusesPapillomavirusPhenotypePropertyProtein BindingProteinsRangeResearch PersonnelRiskRoleSignal PathwaySignal TransductionSolubilitySystemTERT geneTP53 geneTransgenic MiceTransplantationTumor Suppressor ProteinsTumorigenicityVesicleVirusWomananticancer researchbasecaveolin 1costdesignin vivoinsightkeratinocytemouse modelmutantprogramsprotein functionresearch studytraffickingtumorvacuolar H+-ATPase
中文摘要
高危型乳头瘤病毒是人类恶性肿瘤的重要病原体,尤其是宫颈癌。
癌这些致癌病毒编码的E6和E7蛋白已被证明可以调节细胞凋亡。
生长和分化,靶向p53和Rb肿瘤抑制蛋白,并诱导hTERT基因
和细胞永生化。除了E6和E7蛋白,高危乳头瘤病毒还
编码疏水性膜相关E5蛋白。近几个月来,一些研究
E5蛋白的进化与E6蛋白的进化紧密相连,
高风险的乳头状瘤病毒具有将它们与低风险病毒区分开的特征。的
高危型HPV-16 E5蛋白具有广泛的生物学活性,
因子受体周转,MHC转运,内体酸化,锚定非依赖性生长,
细胞间连接通讯以前我们已经表明,E5蛋白结合的一个组成部分,
V-ATP酶复合物,并干扰内体酸化,从而对E5
可能会增强生长因子受体的信号传导。在目前的提案中,我们发现
E5的其他靶点,包括小窝蛋白和116 kDa细胞蛋白。根据我们积累的
关于E5的去污剂溶解特性和鉴定的E5相关蛋白的知识,我们
假设E5分配到膜脂筏中,并与驻留在膜脂筏中的蛋白质结合,
这些信号平台。我们已经构建了一个模型,在概念上将已识别的E5靶点与
过多的已知E5诱导的细胞表型,并基于此设计了实验
模型E5如何靶向筏的具体描述,它如何与特定的筏驻留蛋白结合,
以及它是如何干扰这些蛋白质的功能的,是这项资助的重点。预计各国
对E5功能的深入了解将阐明其与HPV诱导的恶性肿瘤的联系。
英文摘要
The high-risk papillomaviruses are critical etiologic agents in human malignancy, most importantly in cervical
cancer. These oncogenic viruses encode the E6 and E7 proteins that have been shown to modulate cell
growth.and differentiation, target the p53 and Rb tumor suppressor proteins, and induce the hTERT gene
and cellular immortalization. In addition to the E6 and E7 proteins, the high-risk papillomaviruses also
encode the hydrophobic, membrane-associated E5 protein. In recent months, several studies have
established that the evolution of the E5 protein is tightly linked to that of the E6 protein and that the E5 genes
of high-risk papillomaviruses have characteristics that separate them from those of low-risk viruses. The
high-risk HPV-16 E5 protein has a wide spectrum of biological activities, ranging from alterations of growth
factor receptor turnover, MHC transport, endosome acidification, anchorage-independent growth, and
intercellular junction communication. Previously we have shown that the E5 protein binds a component of
the V-ATPase complex and interferes with endosome acidification, thereby giving some insight into how E5
might potentiate the signaling of growth factor receptors. In the current proposal, we have discovered
additional targets for E5, including caveolin and a 116 kDa cellular protein. Based upon our accumulated
knowledge regarding the detergent solubility properties of E5 and the identified E5-associated proteins, we
hypothesize that E5 partitions into membrane lipid rafts and associateswith proteins that are resident in
these signaling platforms. We have constructed a model that conceptually links the identified E5 targets with
the plethora of known E5-induced cellular phenotypes and have designed experiments based upon this
model. The specific delineation of how E5 is targeted to rafts, how it binds to specific raft-resident proteins,
and how is interferes with the functions of these proteins is the focus of this grant. It is anticipated that
insights into E5 functions will illuminate its linkage to HPV-induced malignancy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Conditionally reprogrammed cells as a novel tool for biobanking
-
批准号:8547303
-
项目类别:
-
资助金额:$40.05万
-
财政年份:2013
-
负责人:Richard Schlegel
-
依托单位:
Conditionally reprogrammed cells as a novel tool for biobanking
-
批准号:8899468
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2013
-
负责人:Richard Schlegel
-
依托单位:
Conditionally reprogrammed cells as a novel tool for biobanking
-
批准号:8727495
-
项目类别:
-
资助金额:$37.14万
-
财政年份:2013
-
负责人:Richard Schlegel
-
依托单位:
Emerging Papillomaviruses in Immunosuppressed Dogs
-
批准号:8516613
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2011
-
负责人:Richard Schlegel
-
依托单位:
Emerging Papillomaviruses in Immunosuppressed Dogs
-
批准号:8725249
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2011
-
负责人:Richard Schlegel
-
依托单位:
Emerging Papillomaviruses in Immunosuppressed Dogs
-
批准号:8137493
-
项目类别:
-
资助金额:$39.94万
-
财政年份:2011
-
负责人:Richard Schlegel
-
依托单位:
Emerging Papillomaviruses in Immunosuppressed Dogs
-
批准号:8322566
-
项目类别:
-
资助金额:$39.95万
-
财政年份:2011
-
负责人:Richard Schlegel
-
依托单位:
A topical treatment for genital papillomavirus infections
-
批准号:7286845
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2006
-
负责人:Richard Schlegel
-
依托单位:
A topical treatment for genital papillomavirus infections
-
批准号:7174571
-
项目类别:
-
资助金额:$22.23万
-
财政年份:2006
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:6757107
-
项目类别:
-
资助金额:$31.43万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:7114631
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:7274152
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
Treatment of Cervical Cancer with Artemisinin
-
批准号:6948533
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:7115758
-
项目类别:
-
资助金额:$30.69万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:6949542
-
项目类别:
-
资助金额:$31.43万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
Treatment of Cervical Cancer with Artemisinin
-
批准号:6823604
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
HPV E6 protein regulation of the hTERT promoter
-
批准号:7488862
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2004
-
负责人:Richard Schlegel
-
依托单位:
DNA CONFORMATION DEPENDENT REGULATOR OF GENE EXPRESSION
-
批准号:2896082
-
项目类别:
-
资助金额:$23.6万
-
财政年份:1997
-
负责人:Richard Schlegel
-
依托单位:
CANINE ORAL PAPILLOMAVIRUS--MODEL FOR A VACCINE
-
批准号:2098706
-
项目类别:
-
资助金额:$25.16万
-
财政年份:1992
-
负责人:Richard Schlegel
-
依托单位:
CANINE ORAL PAPILLOMAVIRUS--MODEL FOR A VACCINE
-
批准号:2098705
-
项目类别:
-
资助金额:$23.88万
-
财政年份:1992
-
负责人:Richard Schlegel
-
依托单位:
海外基金